265 related articles for article (PubMed ID: 27121719)
1. Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.
Jung M; Lee J; Kim TM; Lee DH; Kang JH; Oh SY; Lee SJ; Shin SJ
Cancer Res Treat; 2017 Jan; 49(1):44-53. PubMed ID: 27121719
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
[TBL] [Abstract][Full Text] [Related]
3. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.
Cassidy MR; Wolchok RE; Zheng J; Panageas KS; Wolchok JD; Coit D; Postow MA; Ariyan C
EBioMedicine; 2017 Apr; 18():56-61. PubMed ID: 28356222
[TBL] [Abstract][Full Text] [Related]
5. Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.
Jochems A; Leeneman B; Franken MG; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; Groenewegen G; de Groot JWB; Haanen JBAG; Hospers GAP; Kapiteijn E; Koornstra RH; Kruit WHJ; Louwman MWJ; Piersma D; van Rijn RS; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; Uyl-de Groot CA; van der Hoeven KJM
Anticancer Drugs; 2018 Jul; 29(6):572-578. PubMed ID: 29659371
[TBL] [Abstract][Full Text] [Related]
6. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Martens A; Wistuba-Hamprecht K; Geukes Foppen M; Yuan J; Postow MA; Wong P; Romano E; Khammari A; Dreno B; Capone M; Ascierto PA; Di Giacomo AM; Maio M; Schilling B; Sucker A; Schadendorf D; Hassel JC; Eigentler TK; Martus P; Wolchok JD; Blank C; Pawelec G; Garbe C; Weide B
Clin Cancer Res; 2016 Jun; 22(12):2908-18. PubMed ID: 26787752
[TBL] [Abstract][Full Text] [Related]
7. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A
Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study.
Arzu Yaşar H; Turna H; Esin E; Murat Sedef A; Alkan A; Oksuzoglu B; Ozdemir N; Sendur MN; Sezer A; Kılıckap S; Utkan G; Akbulut H; Celik I; Abalı H; Urun Y
J Oncol Pharm Pract; 2020 Mar; 26(2):267-272. PubMed ID: 30924738
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).
Nathan P; Ascierto PA; Haanen J; Espinosa E; Demidov L; Garbe C; Guida M; Lorigan P; Chiarion-Sileni V; Gogas H; Maio M; Fierro MT; Hoeller C; Terheyden P; Gutzmer R; Guren TK; Bafaloukos D; Rutkowski P; Plummer R; Waterston A; Kaatz M; Mandala M; Marquez-Rodas I; Muñoz-Couselo E; Dummer R; Grigoryeva E; Young TC; Schadendorf D
Eur J Cancer; 2019 Sep; 119():168-178. PubMed ID: 31445199
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab prolongs survival in advanced melanoma.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
[No Abstract] [Full Text] [Related]
11. Acute visual loss after ipilimumab treatment for metastatic melanoma.
Wilson MA; Guld K; Galetta S; Walsh RD; Kharlip J; Tamhankar M; McGettigan S; Schuchter LM; Fecher LA
J Immunother Cancer; 2016; 4():66. PubMed ID: 27777775
[TBL] [Abstract][Full Text] [Related]
12. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.
Khoja L; Atenafu EG; Templeton A; Qye Y; Chappell MA; Saibil S; Hogg D; Butler MO; Joshua AM
Cancer Med; 2016 Oct; 5(10):2792-2799. PubMed ID: 27683208
[TBL] [Abstract][Full Text] [Related]
13. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
Zimmer L; Eigentler TK; Kiecker F; Simon J; Utikal J; Mohr P; Berking C; Kämpgen E; Dippel E; Stadler R; Hauschild A; Fluck M; Terheyden P; Rompel R; Loquai C; Assi Z; Garbe C; Schadendorf D
J Transl Med; 2015 Nov; 13():351. PubMed ID: 26541511
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study.
Russi A; Damuzzo V; Chiumente M; Pigozzo J; Cesca M; Chiarion-Sileni V; Palozzo AC
J Chemother; 2017 Aug; 29(4):245-251. PubMed ID: 28398170
[TBL] [Abstract][Full Text] [Related]
15. Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab.
Shreders A; Joseph R; Peng C; Ye F; Zhao S; Puzanov I; Sosman JA; Johnson DB
Cancer Immunol Res; 2016 Jul; 4(7):569-73. PubMed ID: 27197063
[TBL] [Abstract][Full Text] [Related]
16. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma.
Geoerger B; Bergeron C; Gore L; Sender L; Dunkel IJ; Herzog C; Brochez L; Cruz O; Nysom K; Berghorn E; Simsek B; Shen J; Pappo A
Eur J Cancer; 2017 Nov; 86():358-363. PubMed ID: 29100190
[TBL] [Abstract][Full Text] [Related]
18. Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis.
Gambichler T; Brown V; Steuke AK; Schmitz L; Stockfleth E; Susok L
J Eur Acad Dermatol Venereol; 2018 Jun; 32(6):972-977. PubMed ID: 29024038
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ipilimumab for treating advanced melanoma: A systematic review and meta-analysis.
Li J; Gu J
J Clin Pharm Ther; 2019 Jun; 44(3):420-429. PubMed ID: 30693536
[TBL] [Abstract][Full Text] [Related]
20. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.
Middleton MR; Dalle S; Claveau J; Mut P; Hallmeyer S; Plantin P; Highley M; Kotapati S; Le TK; Brokaw J; Abernethy AP
Cancer Med; 2016 Jul; 5(7):1436-43. PubMed ID: 27118102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
